Citadel Advisors
LUNG icon

Citadel Advisors’s Pulmonx LUNG Stock Holding History

Citadel Advisors’s Portfolio LUNG Stock Details LUNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$186K Buy
143,404
+86,395
+152% +$119K ﹤0.01% 12147
2026
Q1 		$73.5K Buy
57,009
+11,752
+26% +$19.4K ﹤0.01% 12223
2025
Q4 		$100K Sell
45,257
-171,919
-79% -$323K ﹤0.01% 11644
2025
Q3 		$352K Buy
217,176
+147,904
+214% +$309K ﹤0.01% 9987
2025
Q2 		$179K Sell
69,272
-114,334
-62% -$451K ﹤0.01% 10782
2025
Q1 		$1.24M Buy
183,606
+82,153
+81% +$582K ﹤0.01% 6497
2024
Q4 		$689K Buy
101,453
+99,154
+4,313% +$653K ﹤0.01% 7869
2024
Q3 		$19.1K Sell
2,299
-147,911
-98% -$1.07M ﹤0.01% 12808
2024
Q2 		$952K Buy
150,210
+16,947
+13% +$130K ﹤0.01% 6683
2024
Q1 		$1.24M Buy
133,263
+78,332
+143% +$918K ﹤0.01% 6499
2023
Q4 		$700K Buy
54,931
+51,377
+1,446% +$535K ﹤0.01% 7397
2023
Q3 		$36.7K Sell
3,554
-6,452
-64% -$74.7K ﹤0.01% 12099
2023
Q2 		$131K Sell
10,006
-153,623
-94% -$1.88M ﹤0.01% 10523
2023
Q1 		$1.83M Buy
163,629
+92,810
+131% +$916K ﹤0.01% 5558
2022
Q4 		$597K Sell
70,819
-71,459
-50% -$680K ﹤0.01% 7869
2022
Q3 		$2.37M Sell
142,278
-121,193
-46% -$2.23M ﹤0.01% 5265
2022
Q2 		$3.88M Buy
263,471
+85,518
+48% +$1.76M ﹤0.01% 4269
2022
Q1 		$4.42M Buy
177,953
+82,432
+86% +$2.13M ﹤0.01% 4423
2021
Q4 		$3.06M Sell
95,521
-350,290
-79% -$12.8M ﹤0.01% 5292
2021
Q3 		$16M Buy
445,811
+178,267
+67% +$7.01M ﹤0.01% 2327
2021
Q2 		$11.8M Buy
267,544
+89,558
+50% +$3.9M ﹤0.01% 2821
2021
Q1 		$8.14M Buy
177,986
+48,241
+37% +$2.77M ﹤0.01% 3298
2020
Q4 		$8.96M Buy
+129,745
New +$6.35M ﹤0.01% 2797

Other funds holding LUNG

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Citadel Advisors's LUNG Position: Q2 2026 in Review

Citadel Advisors increased its Pulmonx (LUNG) stake by 152% in Q2 2026, buying an estimated $119K and bringing the position to 143,404 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #12147.

Citadel Advisors first reported a position in LUNG in Q4 2020 and has held it in 23 quarters since. The position peaked at $16M in Q3 2021. 108 funds tracked by Wall St. Rank hold LUNG as of Q2 2026.

  • Citadel Advisors held 143,404 shares of Pulmonx worth $186K as of Q2 2026.
  • Citadel Advisors bought 86,395 Pulmonx shares in Q2 2026, an estimated $119K.
  • Pulmonx made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12147 holding.
  • Citadel Advisors first reported a position in Pulmonx in Q4 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Pulmonx position peaked at $16M in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Pulmonx as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.